Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset ...

CNW/ - Pfizer Canada is pleased to announce that ABRYSVO, its vaccine for the prevention of Respiratory Syncytial Virus (RSV) ...

RSV vaccination for adults aged 60+ could prevent significant LRTD cases, hospitalizations, and deaths over five years. A ...

Maternal vaccination and immunization with nirsevimab both produce strong increases in infant neutralizing antibody levels ...

Over the past decade, pharmaceutical maker Pfizer ( PFE -0.53%) has severely lagged the market. Dividends reinvested aside, ...

Sanofi has dropped its respiratory syncytial virus (RSV) vaccine for toddlers after the candidate underperformed in a phase 3 ...

A pharmaceutical company trades at 8 times forward earnings with a 7% yield as it raises revenue guidance and reenters the ...

Not just any pharmaceutical stock will do, though. They aren't all created equal. Let's discuss two leaders in the industry that look like strong buys right now: Pfizer (NYSE: PFE) and Eli Lilly (NYSE ...

Key opinion leaders previously interviewed by GlobalData noted the need for more data on current RSV vaccines and their use ...